RenovoRx reports Phase III TIGeR-PaC sub-study data supporting TAMP intra-arterial gemcitabine delivery in pancreatic cancer

RenovoRx

RenovoRx

RNXT

0.00
  • RenovoRx released pharmacokinetic sub-study findings from its Phase III TIGeR-PaC trial in locally advanced pancreatic cancer.
  • Results were published online ahead of presentation at the 2026 ASCO Annual Meeting, scheduled for May 29 to June 2.
  • Targeted intra-arterial gemcitabine delivery via its TAMP platform showed signs of higher local potency with lower systemic exposure versus standard IV dosing.
  • The analysis linked reduced circulating drug levels to a biomarker response signal, supporting a potential tolerability advantage.
  • Data add clinical support for RenovoCath and the TIGeR-PaC program, a key value driver for the company’s oncology pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260830PRIMZONEFULLFEED9725762) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.